Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idarubicin + subcutaneous cytarabine + G-CSF + lisaftoclax for MDS-IB2 and adult secondary or elderly AML
ChiCTR2600131661Phase 4Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Sep 2026
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of lisaftoclax, idarubicin, cytarabine and filgrastim in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), sponsored by Ruijin Hospital. Primary endpoint: Composite Complete Remission. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
lisaftoclaxidarubicincytarabinefilgrastim
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2600131661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600131661.